Dimerix Limited (ASX: DXB) Featured on Channel 7

KEY TAKEAWAYS:

• Dimerix Limited revealed some of the plans for the development of DMX-200 during a recent segment aired on Channel 7.
• Dimerix is in the process of developing DMX-200, a drug therapy for Chronic Kidney Diseases.
• DMX- 2000 will hopefully be released in the market after a series of tests.
• Dimerix successfully completed Phase 2a of the clinical trials of DMX-200 which were published in August and November last year.

Channel 7’s new segment has featured Dimerix Limited during its March 12, 2018 episode. Dimerix, based in Melbourne, Australia, is a biotechnology company is in the process of developing DMX-200, a drug therapy for Chronic Kidney Diseases.

Dimerix successfully completed Phase 2a of the clinical trials of DMX-200 which were published in August and November last year. The company is set to conduct further trials for DMX-200 given its enormous potential to treat
patient with kidney problems.

Despite the completed trials, Dimerix has not provided a specific schedule for making the drug available in the market. The television show, however, hinted that the drug could be out on the market in the next two years.

DMX-200 is said to be a breakthrough therapy that may be able to control some of the major symptoms of Chronic Kidney Disease. Among these symptoms are proteinuria or protein leakage. Researchers from the Harry Perkins Institute of Medical Research came up with the technology that paved the way for the development of DMX-200.

DMX-200 is a result of the laboratory’s Receptor-Heteromer Investigation Technology (Receptor-HIT) which was recently validated by the US Food and Drug Administration (FDA) for its important role in the identification of new treatments.

The new drug aims to fight Chronic Kidney Disease by combining two drugs, one of which is known for its anti-inflammatory properties while the other one is a hormone blocker which is used in treating high blood pressure.

Chronic Kidney Disease is a disease that affects people worldwide and is considered serious as it can lead to kidney failure and even death. Dimerix Limited, which owns Dimerix Bioscience Pty Ltd., is a pharmaceutical company that is committed to developing new therapeutic models with the use of the Receptor-Heteromer Investigation Technology (Receptor-HIT).

About Dimerix Ltd (ASX: DXB)

Dimerix Limited (ASX: DXB) is a clinical-stage drug development company with our lead program DMX-200, currently in Phase II clinical trials for Chronic Kidney Disease (CKD).

Request Info